REGN - Intellia Therapeutics slides after insider selling

Recording the biggest intraday loss in nearly six months, Intellia Therapeutics (NTLA -10.7%) has shed all the gains made since late June when the company and its partner Regeneron (NASDAQ:REGN) showed promising in-vivo CRISPR-based genome editing data for the first time in humans. The weakness could be attributed to the SEC filing submitted by the company director John F. Crowley to indicate the sale of 10,000 company shares. Crowley, who is also the chairman and CEO of Amicus Therapeutics (NASDAQ:FOLD), has executed five transactions on Oct. 05 to sell the shares he acquired through the exercise of options. Companies relying on gene editing are trading sharply lower in morning hours. In addition to Intellia (NASDAQ:NTLA), notable decliners include Graphite Bio (GBIO -2.5%), Editas Medicine (EDIT -10.3%) and CRISPR Therapeutics (CRSP -5.6%). Meanwhile, the field of CAR-T therapy suffered a major setback on Thursday when Allogene (ALLO -42.3%) said that the FDA

For further details see:

Intellia Therapeutics slides after insider selling